Pfizer and Innovent Biologics enter global oncology licensing and collaboration agreement

WHAT CHINWAGY KNOWS

The collaboration
is confirmed.

Pfizer and Innovent Biologics entered a global strategic licensing and collaboration agreement covering research and development of 12 early-stage and de novo oncology medicines, with co-development and co-commercialization opportunities.

Current status

Official collaboration

Known availability

Started 2026-05-28; the official source does not state an end date.

Place

International, Global

Source checked

September 13, 2026